FIRST DAY - EVERY DAY

MuGard is proven to reduce mouth and throat soreness associated with oral mucositis (OM)1

Give patients control in managing their Oral Mucositis

  • Patients should use MuGard 4 to 6 times daily
  • 5 mL of ready-to-use MuGard coats the oral cavity
  • Up to 10 mL can be used if needed
Patients can use MuGard as early as the first day of therapy and throughout therapy or as directed.2

Proven

A phase 4, multicentered, randomized, double-blind, placebo-controlled clinical trial that demonstrated efficacy in reducing mouth and throat soreness1

Proactive

Patients should obtain MuGard® Oral Mucoadhesive before their cancer therapy begins2

Protection

MuGard is a mucoadhesive formulation that forms a protective coating over the oral mucosa1,2

MuGard bottle

Proven

A phase 4, multicentered, randomized, double-blind, placebo-controlled clinical trial that demonstrated efficacy in reducing mouth and throat soreness1

Proactive

Patients should obtain MuGard® Oral Mucoadhesive before their cancer therapy begins2

Protection

MuGard is a mucoadhesive formulation that forms a protective coating over the oral mucosa1,2

Soleva Assist

For more information on how to obtain MuGard, contact Soleva Assist at 877-319-7272

Indication and Important Safety Information

Indication: MuGard® Oral Mucoadhesive is indicated for the management of oral mucositis/stomatitis (that may be caused by radiotherapy and/or chemotherapy) and all types of oral wounds (mouth sores and injuries), including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.

Contraindications: MuGard is contraindicated in patients with known hypersensitivity to any of the ingredients in the formulation.

Special Precautions for Use: Patients should avoid eating or drinking for at least one hour after using MuGard. After use, patients should replace the bottle cap and tightly seal the bottle. This product should not be used after the expiration date shown on the carton and product label. Do not use this product in patients with known sensitivity to any of the product’s ingredients. Dilution of the product prior to use is not recommended.

You may report a MuGard® adverse event to Soleva Pharma at 877-319-7272 or by emailing to
medinfo@solevapharma.com.

Please see accompanying full Prescribing Information.

References: 1. Allison RR, Ambrad AA, Arshoun Y, et al. Multi-institutional, randomized, double-blind, placebo-controlled trial to assess the efficacy of a mucoadhesive hydrogel (MuGard) in mitigating oral mucositis symptoms in patients being treated with chemoradiation therapy for cancers of the head and neck. Cancer. 2014;120(9):1433-1440. 2. MuGard [package insert]. NJ, Soleva Pharma, LLC., 2020.
Soleva Pharma

Soleva Pharma, LLC. | Robbinsville, NJ 08691
Soleva Pharma and the logo designs presented in this material are trademarks of Soleva Pharma, LLC.
MuGard is a trademark of Soleva Pharma.
©2020 Soleva Pharma, LLC. DN-1256-0630